CorMedix: Q1 net loss $7.0M; FDA accepts DefenCath NDA resubmission with 6-mo review

CorMedix Inc.

Net loss $7.0M ($0.18/shr) vs $7.2M ($0.20/shr) in Q1 2021; operating expenses down 3%.
FDA accepted DefenCath NDA resubmission as complete Class 2 response with 6-month review; inspection planned.
New CEO Joe Todisco officially started May 10; CCO Tom Nusbickel departed by mutual agreement.
Donna Ucci (SVP Global Quality) and Frank Raffaele (VP Supply Chain) hired; Liz Hurlburt promoted.
Winding down European ops, discontinuing Neutrolin distribution to focus on US DefenCath launch.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.